Pfizer said US regulators have cleared it to proceed with its offer to acquire obesity startup Metsera, upping the pressure on Novo, which is attempting to make a rival bid https://t.co/4BuaCavETR ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has closed the syndication of its US$100 million secured revolving credit facility (“the Credit Facility”). On June 17, 2025, Knight had announced that it had closed a US$50 Million revolving credit facility with National Bank of Canada (“NBC”) and initiated a syndication process to increase the size of the facility. As ...

Core Viewpoint - Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming that Metsera breached its merger agreement obligations by declaring Novo's $8.5 billion bid as a superior offer [1][2]. Group 1: Legal Action and Implications - Pfizer is seeking a temporary restraining order from a Delaware court to prevent Metsera from terminating the merger agreement [1]. - The lawsuit alleges that Novo's bid represents an illegal attempt to circumvent antitrust scrutiny, posing significant regulatory risks [2]. Group 2: Market Context and Strategic Moves - Pfizer has received early antitrust clearance for its proposed $7.3 billion acquisition of Metsera from the U.S. Federal Trade Commission, with the waiting period under the Hart-Scott-Rodino Act terminated ahead of the November 7 deadline [3]. - The obesity market is projected to reach $150 billion by the early 2030s, and Pfizer aims to enter this fast-growing sector [3]. - Pfizer is looking to offset declining COVID-related revenues and impending patent expirations by acquiring Metsera, which has faced setbacks in developing its own treatments [4]. Group 3: Competitive Landscape - Novo Nordisk, known for its weight-loss drugs Wegovy and Ozempic, is attempting to recover market share lost to Eli Lilly, whose drugs Zepbound and Mounjaro have demonstrated stronger clinical results [4]. - Metsera's pipeline includes experimental GLP-1 and amylin-based therapies, which analysts estimate could achieve peak sales of $5 billion [4].

Core Viewpoint - The lawsuit claims that Novo Nordisk's acquisition offer for drug startup Metsera is unlikely to be completed successfully [1] Group 1 - The lawsuit raises concerns about the feasibility of Novo Nordisk's offer for Metsera [1]

(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer. Metsera has declared Novo's offer superior, and given Pfizer until Tuesday to raise its bid. The U.S. Federal Trade Commission granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews. The waiting period was originally set to e ...

Core Insights - Teva Pharmaceutical Industries Ltd. will have its President and CEO, Richard Francis, present at two investor conferences in November 2025 [1][4] Company Overview - Teva is a leading innovative biopharmaceutical company with a strong generics business, committed to improving health for over 120 years [2] - The company focuses on neuroscience, immunology, complex generic medicines, biosimilars, and pharmacy brands globally [2] Upcoming Events - Richard Francis will present at the UBS Global Healthcare Conference on November 10, 2025, at 8:45 A.M. ET [4] - He will also present at the Jefferies London Healthcare Conference on November 18, 2025, at 11:00 A.M. GMT (6:00 A.M. ET) [4]

TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin†or the "Company†), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, is pleased to announce that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the Company (a "Common Share†) and, in lieu of Common Shares to certa. ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin†or the "Company†), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, is pleased to announce that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the Company (a "Common Share†) and, in lieu of Common Shares to certa. ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which did not meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between January 16, 2025, and September 12, 2025 [1]. - Defendants allegedly made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a stock price decline from $6.03 to $1.02, an 83.2% drop in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].